SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The tables below present segment information reconciled to total Company financial results, with segment operating income or loss including gross profit less direct research and development expenses and direct selling expenses as well as any litigation settlements, to the extent specifically identified by segment (in thousands):

Three Months Ended March 31, 2016	Impax Generics		Impax Specialty Pharma		Corporate and Other			Total Company
Revenues, net	$	170,079	$	55,429	$	—		$	225,508
Cost of revenues	$	110,122	$	12,796	$	—		$	122,918
Selling, general and administrative	$	4,774	$	13,818	$	25,706		$	44,298
Research and development	$	14,595	$	4,427	$	—		$	19,022
Patent litigation expense	$	114	$	1,205	$	—		$	1,319
Income (loss) before income taxes	$	40,474	$	23,183	$	(81,151	)	$	(17,494	)

Three Months Ended March 31, 2015	Impax Generics		Impax Specialty Pharma			Corporate and Other			Total Company
Revenues, net	$	128,741	$	14,355		$	—		$	143,096
Cost of revenues	$	76,472	$	7,390		$	—		$	83,862
Selling, general and administrative	$	4,286	$	14,856		$	31,018		$	50,160
Research and development	$	10,863	$	4,099		$	—		$	14,962
Patent litigation expense	$	778	$	182		$	—		$	960
Income (loss) before income taxes	$	36,342	$	(12,172	)	$	(34,875	)	$	(10,705	)